Mocertatug rezetecan: Clinical Trials

3 recruiting, 1 not yet recruiting. 4 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	4	Recruiting 3, Not yet recruiting 1

Follow Mocertatug rezetecan: new trials by email Literature Review of Mocertatug rezetecan trials Research Report on Mocertatug rezetecan

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] Mocertatug rezetecan, Bevacizumab - Ovarian Neoplasms	Phase 3	Not yet recruiting	GlaxoSmithKline	720	2026-10-09	2026-10-02
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) Mocertatug rezetecan, Dostarlimab, Pembrolizumab - Neoplasms, Endometrial	Phase 3	Recruiting	GlaxoSmithKline	610	2026-09-24	2026-10-15
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms	Phase 3	Recruiting	GlaxoSmithKline	450	2026-06-18	2026-10-15
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) Mocertatug rezetecan, Paclitaxel, Doxorubicin - Neoplasms, Endometrial	Phase 3	Recruiting	GlaxoSmithKline	600	2026-06-04	2026-10-02

Conditions studied

Endometrial Neoplasms (2)  ·  Ovarian Neoplasms (2)

Sponsors

GlaxoSmithKline (4)

Countries

Japan (4)  ·  Argentina (2)  ·  Australia (2)  ·  Canada (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Brazil (1)  ·  Israel (1)  ·  Panama (1)  ·  United States (1)

NIH funding

2025 (4)